Danaher Corporation
DHR · NYSE
$208.74-$10.184.74%
$208.74$0.000.00%
DHR · NYSE
Danaher sells life-science research instruments and consumables, diagnostic systems, and bioprocessing technologies. Its customers include pharmaceutical and biotechnology companies, research laboratories, hospitals, and other healthcare providers. Revenue is generated through instrument sales, recurring consumables and service revenue, and products used in biomanufacturing and diagnostics. The supplied evidence does not provide the contribution of each operating segment, customer concentration, or installed-base statistics. Danaher reported $24.6 billion of fiscal 2025 revenue and $3.6 billion of net income, compared with $23.9 billion and $3.9 billion, respectively, in fiscal 2024.
Danaher fell $4.27, or 2.15%, from $199.05 on July 28 to $194.78 on August 4. The decline was orderly at first: shares dropped to $196.49 on July 29, slipped to $196.17 on July 30, and reached $194.98 on July 31. Danaher then recovered to $197.50 on August 3 before giving back that gain and falling $2.72 on August 4, with volume rising to 6.97 million shares from 2.95 million the prior session. The supplied evidence contains no Danaher-specific announcement explaining the move. It also provides no broader-market benchmark or sector catalyst, so the week appears to have been trading-driven rather than tied to an identified company event.
Major Acquisition Alert: Julie A. Sawyer Montgomery Acquires $1.93M In Danaher Stock Options
